ANGPTL4 and Psoriasiform dermatitis: Compared with the IMQ group, the intradermal injection with recombinant ANGPTL4 protein significantly exacerbated the clinical phenotype of IMQ-induced psoriasiform dermatitis, which included redness, thickening, and scaling of the skin (Figure 9B).